Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-05-27
2008-05-27
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07378249
ABSTRACT:
The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.
REFERENCES:
patent: 3666646 (1972-05-01), Lampson et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5298614 (1994-03-01), Yano et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 6780429 (2004-08-01), Matsuyama et al.
patent: 2003/0165479 (2003-09-01), Velleca et al.
patent: 2003/0166001 (2003-09-01), Lipford et al.
patent: 2004/0121348 (2004-06-01), Kreutzer et al.
patent: 2006/0134128 (2006-06-01), Seya et al.
patent: 2006/0147456 (2006-07-01), Lebecque et al.
patent: 113162 (1989-07-01), None
patent: 281380 (1995-11-01), None
patent: 1 577 383 (2005-09-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 01/90151 (2001-11-01), None
patent: WO 03/31573 (2003-04-01), None
patent: WO 03/031573 (2003-04-01), None
patent: WO 2004/053057 (2004-06-01), None
patent: WO 2004/053452 (2004-06-01), None
patent: WO 2004/094671 (2004-11-01), None
patent: WO 2006/010838 (2006-02-01), None
patent: WO 2006/014653 (2006-02-01), None
Schmidt et al (J. Immunol., 1/4, 172(1): 138-143).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Gura (Science, 1997, 278:1041-1042.).
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Lewin, B. also teaches (Genes VI, Oxford University Press, Inc., NY, Chapter 29, 1997).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Mallampalli et al. (Biochem. J. vol. 318, 1996, pp. 333-341).
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Andre et al (Journal of Clinical Oncology, Jul. 15, 2004, 22(14s): 9619).
Yakes et al (Cancer Research, 62:4132-4141, 2002).
Alexopoulou, L. et al. “Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3”,Nature, Oct. 18, 2001, pp. 732-738, vol. 413.
Chaturvedi, S. et al. “Stabilization of triple-stranded oligonculeotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages”,Nucleic Acids Research, 1996, pp. 2318-2323, vol. 24, No. 12.
Field, A. et al. “Inducers of interferon and host resistance, IV. Double-stranded replicative form (MS2-RF-RNA) fromE. coliinfected with MS2 coliphage”,Proc. Natl. Acad. Sci. U. S. A., Nov. 1967, pp. 2102-2108, vol. 58, No. 5.
Field, A. et al. “Inducers of interferon and host resistance, II. Multistranded synthetic polynucleotide complexes”,Proc. Natl. Acad. Sci. U. S. A., Sep. 1967, pp. 1004-1010, vol. 58, No. 3.
Field, A. et al. “Inducers of interferon and host resistance, V. In vitro studies”,Proc. Natl. Acad. Sci. U. S. A., Sep. 1968, pp. 340-346, vol. 61, No. 1.
Gil, J. et al. “Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the α subunit of eukaryotic translation initiation factor 2 and NF-κB”,Molecular and Cellular Biology, Jul. 1999, pp. 4653-4663, vol. 19, No. 7.
Kandimalla, E.R. et al. “Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribnucleotide agents with distinct cytokine induction profiles”,Nucleic Acids Research, 2003, pp. 2393-2400, vol. 31, No. 9.
Niwa, M. et al. “A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response”,Cell, Dec. 23, 1999, pp. 691-702, vol. 99.
Peyrottes, S. et al. “Oligodeoxynucleoside phosphoramidates (P-NH2): synthesis and thermal stability of duplexes with DNA and RNA targets”,Nucleic Acids Research, 1996, pp. 1841-1848, vol. 24, No. 10.
Tytell, A. et al. “Inducers of interferon and host resistance, III. Double-stranded RNA from reovirus type 3 virions (REO 3-RNA)”,Proc. Natl. Acad. Sci. U. S. A., Oct. 1967, pp. 1719-1722, vol. 58, No. 4.
Adams, M. et al. “The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TRL3) agonist and tumour-derived exosomes in advanced ovarian cancer”,Vaccine, 2005, pp. 2374-2378, vol. 23.
Andre, F. et al. “Targeting Toll like receptor 3 by double standard RNA in breast cancer: Results from in vitro studies and randomized trial”,J. Clinical Oncology, Jul. 15, 2004, p. 9619, vol. 22, No. 14S, XP009051335.
Cho, C. H. et al. “Monophosphoryl lipid A, Polyadenylic-polyuridylic Acid Cisplatin”J. Korean Soc. Microbiol, 1994, pp. 231-244, vol. 29, No. 2.
Khan, A. et al. “Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy”,Surgery, Sep. 1995, pp. 531-538, vol. 118, No. 3.
Salazar, A. M. et al. “Long term treatment of malignant gliomas with intramusculary administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study”Neurosurgery, Jun. 1996, pp. 1096-1104, vol. 38, No. 6.
Wen, L. et al. “The Effect of Innate Immunity on Autoimmune Diabetes and the Expression of Toll-Like Receptors on Pancreatic Islets”,The Journal of Immunology, 2004, pp. 3173-3180, vol. 172.
Whitmore, M. et al. “Synergistic Activation of Innate Immunity by Double-Stranded RNA and CpG DNA Promotes Enhanced Antitumor Activity”,Cancer Research, Aug. 15, 2004, pp. 5850-5860, vol. 64.
Youn, J. et al. “Adjuvant Treatment of Operable Stomach Cancer with Polyadenylic Polyuridylic Acid in Addition to Chemotherapeutic Agents: A Preliminary Report”,Int. J. Immunopharmac., 1990, pp. 289-295, vol. 12, No. 3.
Field, A. K. et al. “Invited Discussions: Double-Stranded Polynucleotides as Interferon Inducers”J. Gen. Physiol.,. 1970, pp. 90s-96s, vol. 56.
Andre Fabrice
Sabourin Jean-Christophe
Zitvogel Laurence
Aeder Sean E
Institut Gustave Roussy
Saliwanchik Lloyd & Saliwanchik
Yu Misook
LandOfFree
Treatment of cancer using TLR3 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancer using TLR3 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer using TLR3 agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2807792